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and an annual knee X-ray, with 445 of them needing a knee brace during this period. 
During the study period there were 6,705 osteoarthritis-related hospitalizations, 
and over 10,000 combined physiotherapy(PT)/occupational therapy (OT) and home 
care nursing visits among patients prescribed HA. Hylan G-F 20 patients had fewer 
visits to a GP (36%) and specialist (39%), lower use of PT/OT (23% and 1%) and home 
care nursing (2%) services compared to other HA treatments (p< 0.05 for all com-
parisons). ConClusions: This analysis demonstrates that not all HA injections 
in patients with knee osteoarthritis represent similar resource utilization. Further 
real world examination of the effectiveness of HA for reducing clinical symptoms 
and improving health care resource utilization in knee osteoarthritis is warranted.
Muscular-skeletal DisorDers – Patient-reported outcomes & Patient 
Preference studies
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objeCtives: The objective of this research report was to examine the relation-
ship between medication adherence levels and health care cost among patients 
with rheumatoid arthritis (RA). Methods: This study used a retrospective case 
comparison design to examine per member per month (PMPM) medical cost. The 
commercial population of patients with RA was extracted from two large claims 
data bases between years 2006 and 2009. The case cohort consisted of compliant 
patients (MPR ≥ 80%) receiving medication management from the Specialty divi-
sion of a large pharmacy retail chain. The comparison cohort consisted of non-
compliant patients (MPR < 80%) from a national benchmark pharmacy and medical 
claims data base. Using propensity scores, patients were matched on age, gender, 
risk score, socio-economic status, standard industrial classification code, comorbid 
conditions, and pre-medication gap. This process resulted in 512 one-to-one match 
pairs. Results: Patients with RA who were compliant to their medication regimen 
had 25% lower PMPM medical cost (in-patient, out-patient, professional, and emer-
gency room cost) than patients who were non-compliant ($637 vs. $855 respectively; 
P= 0.0458). The majority of this cost difference was due to in-patient cost which was 
46% lower for compliant patients, followed by professional cost which was 15% 
lower for compliant patients. A closer look at medical cost by levels of compliance 
reveals that PMPM medical cost decreased at each level of medication compliance 
described below. Patients with adherence levels less than 40% had PMPM cost of 
$1024, those with adherence levels between 40% and 80% had PMPM cost of $838, 
and patients with adherence levels greater than or equal to 80% had PMPM cost of 
$637. ConClusions: Medical cost decreases as adherence to the RA medication 
regimen increases. Given that the cost of treating RA can be extremely expensive, 
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objeCtives: The International Costs and Utilities Related to Osteoporotic fractures 
Study (ICUROS) is an ongoing 18 months prospective observational study with the 
objective of estimating resource use and health related quality of life related to osteo-
porotic fractures. This study aims to describe the resource utilization after vertebral 
fractures (sustained during 2007-2012) pooled from nine countries: Australia, Austria, 
France, Italy, Lithuania, Mexico, Russia, Spain, and the UK. Methods: Patients stud-
ied were ≥ 50 years and lived at home prior to fracture. Data were collected through 
patient interviews and review of medical records: at baseline, 4, 12, and 18 months after 
fracture. Only resource use related to the fracture event was collected. Results: There 
were 636, 572, and 536 patients available for analysis at 4, 12 and 18 months follow-up, 
respectively. The mean age (±SD) at fracture was 70±10 years and 81% were women. 
45% of patients were hospitalized. Mean hospital length of stay (LoS) (±SD) was 5.7±12.4 
days during months 0-4 and 0.9±9.8 during months 5-18. The mean number of physi-
cian visits (±SD) was 2.8±2.7 during months 0-4 and 1.9±3.4 between months 5-18. The 
mean number of nurse visits (±SD) was 1.4±8.5 and 1.5±19.9 during the corresponding 
periods, respectively. During months 0-4, 72% of patients used analgesics, 59% calcium/
vitamin D, and 41% pharmacological interventions for osteoporosis. The respective 
uptakes for months 5-18 were 56%, 55% and 34%. ConClusions: The majority of 
health care consumption related to vertebral fracture occurs during the first 4 months 
but substantial consumption persists up to 18 months after fracture.
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objeCtives: Musculoskeletal conditions are the primary cause of physical disability 
in the United States, and have implications for workplace productivity and employer 
health costs. This study determined the influence of employer-sponsored, onsite 
chiropractic care on health care utilization. Methods: A retrospective claims anal-
ysis of members of an employer-sponsored health plan receiving chiropractic care 
exclusively onsite or offsite from 2010-2012. Data were obtained from the employ-
er’s health benefits administration program. Eligible participants had continuous 
enrollment in the health plan and ≥ 1 billing code for chiropractic services during 
the 36-month study period. Utilization was assessed in 2 categories: radiological 
procedures and clinical care. Utilization differences were evaluated by having ≥ 1 
health care event in any category. Continuous variables were summarized as means, 
and binary variables as counts and proportions. Differences were assessed via chi-
square test for categorical variables and t-test and Kruskal-Wallis non-parametric 
test for continuous variables. Comparisons were considered significant at alpha = 
0.05. Results: The analysis included 876 onsite and 759 offsite participants. The 
populations were similar in gender; the onsite group was slightly younger. The 
offsite group received more radiology services overall (55.5% vs 38.2%, P< 0.001) 
including x-ray (46.0% vs 26.6%; P < 0.0001); ultrasound (15.8% vs 10.7%, P< 0.0001), 
and magnetic resonance imaging (14.6% vs 12.4%, P< 0.0001); had higher outpatient 
(47.3% vs 30.2%, P< 0.0001) and emergency department (19.0% vs 13.1%; P = 0.022) uti-
lization; and demonstrated greater use of chiropractic care (mean 15.2 vs 9.16 visits; 
P< 0.0001) and physical therapy (mean 9.6 vs 1.5 visits; P< 0.0001). ConClusions: 
In patients needing chiropractic care, those utilizing onsite services had lower 
health care utilization, including radiology services , clinical care, and counts of 
chiropractic and physical therapy services. The study results support the value of 
chiropractic services offered at onsite health centers, where more tightly managed 
and evidence-based approaches to musculoskeletal conditions can be facilitated.
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objeCtives: To examine the health care resource utilization in patients with knee 
osteoarthritis and treated with Hylan G-F 20 (Synvisc, Genzyme Biosurgery) com-
pared with patients treated with alternative intra-articular hyaluronic acid (HA) 
injections in Ontario, Canada. Methods: This is an observational, prospective 
cohort of patients 18 years and older who, between June 1, 1999 and December 31, 
2012 had: 1) a diagnosis of knee osteoarthritis identified by ICD 9-10 or text coding; 2) 
received at least 1 treatment cycle with intra-articular HA and; 3) complete pain and 
mobility data for each treatment cycle. Data from the Southwestern Ontario (SWO) 
database, has been continuously compiled since 1999 and includes demographic, 
biometric, laboratory, diagnostic and health resource measures as collected in a 
primary care setting. Health care resource utilization included clinic visits, emer-
gency visits, hospitalizations, home care visits, knee bracing, radiographs, and work 
absenteeism. Differences between treatments were compared using independent 
sample t-tests. Results: 6,618 patients met all inclusion criteria of which 44% 
were treated with Hylan G-F 20. Patients were similar across treatment groups. 
During the follow-up period, patients received, on average, 6 HA treatment cycles 
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objeCtives: Establish the Compliance Questionnaire Rheumatology (CQR) poten-
tial value as a predictive adherence tool by identifying similarities, differences 
and overall relationship between the CQR and the Morisky Medication Adherence 
Scale (MMAS-4). Methods: Patients residing in the United States completed a self-
administered, Internet-based questionnaire in the fall of 2011. Patients self-reported 
a diagnosis of rheumatoid arthritis (RA). The cross sectional survey included the 
CQR, MMAS-4 and extensive treatment and demographic patient level data. CQR 
predicts patients that are likely to be adherent at 50%, 60%, 75%, 80%, 85%, 90% or 
95% levels. The MMAS-4 is scored from 0-4, with zero equal to perfect adherence. 
Frequency distributions were compared. Linear models looked at: inter-item cor-
relations, CQR score thresholds optimally differentiating adherent vs. non-adherent 
on MMAS-4, and ordinary least squares (OLS) analysis of the ability of the CQR to 
predict MMAS-4 scores. Results: Survey respondents were 76.2% female, 86.2% 
Caucasian, with mean age 56.4 years. Frequency distributions of the CQR and 
MMAS-4 were similar. The CQR provided much more detail at high adherence levels, 
and hence appears more discriminative in these patients. Comparing dichotomous 
adherent/non-adherent results, the optimal CQR threshold for predicting “adher-
ent patients” from MMAS-4, was 60%. Correlation between MMAS-4 and CQR was 
0.40. CQR scores can predict MMAS-4 scores, although the relationship appears 
weak. ConClusions: Compared with MMAS-4, the CQR scale appears to be more 
sensitive at high levels of adherence. The CQR appears to be useful as a predictive 
tool. It does not require claims-based data to assess historical non-adherence, and 
so may be a useful alternative. These results warrant further exploration of the 
CQR as a way to stream rheumatology patients into appropriate treatment, based 
on their potential to be non-adherent.
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objeCtives: The aim of this study is to assess adherence among patients attended 
by the Secretary of State for Health of Minas Gerais (SES / MG) between 2008 and 2010 
with a diagnosis of osteoporosis and describe the cost of non-adherence to treat-
ment. Methods: A retrospective cohort study from a database for administrative 
purposes of the SES / MG was made. Selected patients with a diagnosis of osteoporo-
sis in postmenopausal, with at least three records of dispensing drugs and age equal 
to or greater than 40 years. We calculated adherence to treatment considering the 
range of dispensing drugs. Then we proceeded to calculate the cost of non-adher-
ence from demographics and cost in Minas Gerais, Brazil. Results: 3905 patients 
were taking alendronate sodium distributed by Unified Health System Adherence 
to treatment of osteoporosis in Minas Gerais was 80 % and 20 % of irregular adher-
ence. Non-adherence to treatment increases by 20,4% the total cost of osteoporosis, 
considering pharmacological treatment and hospital treatment. ConClusions: 
Adherence to treatment is an important component of treatment effectiveness. 
Poor adherence is related to high treatment costs and high incidence of osteoporo-
tic fractures. The use of administrative databases allows the evaluation of health 
programs, especially programs for dispensing medicines. Measures that increase 
adherence to drug treatment should be taken to reduce the costs and improve the 
effectiveness of osteoporosis treatment.
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objeCtives: i) estimate the MCID for EQ-5D in patients with chronic widespread 
pain; ii) estimate the MECD for patients undergoing cognitive behavior therapy 
(CBT), prescribed exercise therapy (EX), and combination therapy, i.e. cognitive 
behavior therapy and prescribed exercise together (COMB). Methods: Using data 
from a multi-center RCT, MCID was estimated through regression analysis and ROC 
curves. Moreover, average change, minimum detectable change and change dif-
ference approaches were applied. The minimum cost-effective difference (MCED) 
for the three patients’ subgroups allocated to each of the active treatments of the 
trial was estimated through ROC curve approach and through regression analysis. 
The MCED was computed using a threshold of £20,000-£30,000 per QALY as cost-
effectiveness anchor. Ordinary least squares was used in regression analysis while 
ROC were estimated based on logistic analysis Results: Estimates of MCID range 
between .05 and .33. Adopting a cost-effectiveness threshold of £20,000/QALY, 
the MCED was equal to .226, .062 and .104, for CBT, EX and COMB respectively. 
Adopting a cost-effectiveness threshold of £30,000/QALY, the MCED equaled .315, 
.067 and .119, for CBT, EX and COMB, respectively. However, estimates were sensi-
tive to the choice of the anchor and the estimation method. ConClusions: The 
minimal important difference (MID) represents the smallest amount of benefit 
that the patient can recognize and value. It is useful in the design of clinical trials 
for sample size calculations and in the interpretation of results. However, it does 
not help in the allocation of health care resources. Minimum cost-effective dif-
ference (MCED) can be used to bridge MCID and cost-effectiveness, being defined 
as the smallest improvement in the HR-Qol instrument associated with a cost-
effective outcome. MCED allows understanding whether the minimum change 
perceived as meaningful is cost-effective, given a certain acceptability threshold. 
objeCtives: This study reports real-world utilization patterns observed for rheuma-
toid arthritis (RA), psoriatic arthritis (PSA), and ankylosing spondylitis (AS) patients 
treated with golimumab (GLM). Methods: Patients with an ICD-9 code for RA, PSA, 
or AS receiving ≥ 2 fills of GLM as their first biologic medication (bionaive) or most 
recent biologic medication (bio-experienced) were identified between 1/1/2008 and 
12/31/2010 in a large health care claims dataset (Truven Health). Patient characteris-
tics and refill patterns were summarized using descriptive statistics .The proportion 
of adherent refills was calculated as the number of refills occurring between 21and 
38 days from a previous fill divided by the total refill intervals. Results: A total of 
1,515 patients with ≥ 2 GLM fills and a diagnosis of RA (n= 1,036), PSA (n= 325) or AS 
(n= 154) were identified in the database. Median age was: RA 52 years; PsA 50 years; 
AS 47 years. The majority were bio-experienced (RA 72%; PsA 79%; AS 79%). A total 
of 13,738 GLM refills were observed (RA 9,398; PsA 2,961; AS 1,369). The number of 
refills per patient ranged from 2 to 34 with a mean (SD) of 10.1 (7.25) and median 
of 8. The mean (SD) interval for all refills was 34.8±13.0 days; median was 31 days. 
Median refill interval for RA, PsA and AS was 31 days in bio-experienced subgroups 
and 32 days for bionaive subgroups. The proportion of adherent refills overall was 
78%; (RA 79%; PSA 76%; AS 78%). The proportion of adherent refills appeared similar 
for bionaive and bioexperienced patients except in the AS group (bionaive 73.8%; 
bioexperienced 79.3%). ConClusions: This retrospective observational study con-
firms earlier findings that GLM is utilized largely in patients who have used other 
biologic medications. A high proportion of GLM-treated patients were adherent to 
refilling medication and median refill intervals occurred as recommended in the 
GLM prescribing information.
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objeCtives: To evaluate patient characteristics and real-world treatment patterns 
of subcutaneous anti-TNF medications for patients enrolled in Humana’s commer-
cial and Medicare patient populations. Methods: Adult patients (aged ≥ 18 years) 
with ≥ 2 fills of index biologic (adalimumab (ADA), certolizumab (CTZ); etanercept 
(ETA) or golimumab (GLM)) in the post-index period, and continuous eligibility for ≥ 6 
months pre- and 12 months post-index were identified in health care claims. Patient 
age, gender, RxRisk-V score, biologic use and disease modifying anti-rheumatic 
drug (DMARD) use history in the pre-index period were summarized. Utilization 
measures included monthly biologic dose, refill interval, proportion of adherent fills 
(refilled ± 7 days of expected), and proportion of patients with 100% refill adherence. 
Descriptive statistics (mean, SD, n, %), one-way analysis of variance (continuous 
variables), and chi-squared tests (categorical variables) were employed. Results: 
3,568 ADA, 287 CTZ, 3,625 ETA, and 158 GLM patients were studied. The CTZ and 
GLM groups were significantly younger than all others (p< 0.001). The GLM group 
had a higher proportion with prior biologic use (58.2%) vs. ADA (11.1%), CTZ (34.1%), 
and ETA (4.9%); (p< 0.0001). The GLM group had higher mean Rx Risk-V scores as 
compared to ETA (6.51±3.47 vs. 5.94±3.14, respectively; p< 0.05) and had higher pro-
portions of patients with pre-index DMARD use (71.5%) vs. ADA (57.1%), CTZ (54.4%) 
and ETA (52.1%); (p< 0.001). The proportion of patients with 100% of compliant refills 
was significantly greater in the GLM group (39.9%) than ADA -28.6%; CTZ-21.6%; 
ETA-27.3%; p< 0.001) and was statistically lower in the CTZ group as compared to 
all others (p< 0.05). ConClusions: A number of statistically significant differences 
were identified. Golimumab use was associated with a higher proportion of patients 
achieving 100% refill compliance compared to other subcutaneous anti-TNF medica-
tions. The implications of differences in clinical and demographic characteristics 
and medication adherence on patient outcomes require further exploration.
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objeCtives: To study 1-year treatment persistence among patients with rheuma-
toid arthritis (RA), initiating biologics (etanercept or adalimumab) with or without 
non-biologic disease modifying anti-rheumatic drugs (NbDMARDs). Methods: 
Adult (≥ 18 years) patients with RA newly treated with etanercept or adalimumab 
with ≥ 360 days continuous enrolment before and after their first (index) biologic 
claim were identified in the MarketScan® Research Databases (Jan 1, 2010-Dec 31, 
2011) and the Optum Research Database (Jan 1, 2009-Oct 1, 2011). Patients with a 
claim for a biologic in the 360 days pre-index or treated with biologics for conditions 
other than RA were excluded. Monotherapy patients met the following criteria at 
index: 1) Initiated monotherapy; no claim for a NbDMARD 360 days pre- and up to 30 
days post-index or 2) Switched to monotherapy; ≥ 1 claim for a NbDMARD between 
day -360 and -30 (pre-index) and no claims for a NbDMARD between day -29 and 
+30. Combination therapy patients met the following criteria: 1) Initiated combi-
nation therapy; no claims for NbDMARDs from day -360 to -30 and ≥ 1 claim for a 
NbDMARD from day -29 to +30 or 2) Switched to combination therapy; ≥ 1 claim for 
a NbDMARD between day -360 and -30, and another claim for a NbDMARD from day 
-29 to +30. Persistence was defined as the number of days from the index date until 
the earlier of a 45-day gap in therapy or a switch to another biologic. Results: Of 
6,626 patients in the MarketScan and 2,426 patients in the Optum databases, 35.7% 
and 36.9% were on biologic monotherapy respectively. Persistence was similar in 
both databases and higher with combination therapy (Truven/Optum: 45.1%/48.6% 
etanercept, 42.6%/47.0% adalimumab) than with monotherapy (Truven/Optum: 
35.5%/43.1% etanercept, 35.1%/44.0% adalimumab). ConClusions: Combination 
therapy was associated with greater persistence than biologic monotherapy.
